Welcome to our dedicated page for Illumina SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Illumina Inc (ILMN) SEC filings, offering a view into the company’s regulatory disclosures, financial reporting, and material corporate events. Illumina’s common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol ILMN, as noted in multiple Form 8-K filings.
Investors and analysts can use this filings feed to review Illumina’s current and historical reports, including Forms 10-K and 10-Q referenced in company press releases, as well as Form 8-K filings that detail significant events. Recent 8-Ks describe preliminary unaudited financial results, quarterly earnings announcements, and capital markets transactions such as the issuance of 4.750% notes due 2030 under an existing indenture, along with expected uses of proceeds for general corporate purposes and potential acquisitions.
Filings also outline material agreements and strategic transactions. For example, an 8-K dated June 22, 2025 describes a Stock Purchase Agreement under which Illumina will acquire Standard BioTools’ aptamer-based and functional proteomics business, including SomaLogic, subject to regulatory approvals and customary closing conditions. These documents provide details on purchase price, milestone payments, regulatory conditions, and termination provisions.
On Stock Titan, SEC filings for Illumina are paired with AI-powered summaries designed to highlight key elements of each document. Users can quickly identify important information in annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), as well as access data on registered securities and capital structure. Real-time updates from EDGAR ensure that new filings, including any future debt offerings, material agreements, or other reportable events, appear promptly, while AI-generated overviews help readers navigate complex regulatory language more efficiently.
ILLUMINA, INC. director Scott B. Ullem acquired additional company stock as part of his board compensation. On March 31, 2026, he received 190 shares of common stock valued at $131.5473 per share, issued in lieu of his first quarter 2026 cash retainer fees. Following this award, he directly holds 8,791 shares of Illumina common stock. According to the footnote, Mr. Ullem elected to receive 100% of his 2026 board and committee cash retainer fees in Illumina stock, with the number of shares based on the volume weighted average closing price during the completed quarter. This is a compensation-related grant rather than an open-market purchase.
Meister Keith A. reported acquisition or exercise transactions in this Form 4 filing.
ILLUMINA, INC. director Keith A. Meister received 161 shares of common stock as a stock-based retainer on March 31, 2026. He elected to take 100% of his 2026 board and committee cash retainer fees in Illumina stock, with the share amount based on the volume weighted average closing price for the completed quarter of $131.5473 per share.
Following this grant, he holds 4,566 shares directly and reports 3,829,508 shares held indirectly for the accounts of certain Corvex Funds for which Corvex Management LP acts as investment adviser.
Illumina, Inc. announced upcoming changes to its Board of Directors, with three current members planning to retire at the 2026 annual meeting of stockholders.
Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire effective May 21, 2026, and the company states their retirements are not due to any dispute or disagreement with the company or its Board.
The Board has nominated David P. King, a former CEO and Executive Chairman of Laboratory Corporation of America with extensive healthcare and life sciences board experience, to stand for election as a director at the 2026 annual meeting.
Illumina Inc: The Vanguard Group filed an amendment to its Schedule 13G disclosing zero shares of Illumina common stock beneficially owned following an internal realignment effective January 12, 2026. The filing states Vanguard subsidiaries that formerly reported with The Vanguard Group will now report separately in reliance on SEC Release No. 34-39538.
Illumina, Inc. SVP and Chief Technology Officer Steven Barnard reported equity awards in the form of restricted stock units and performance stock units. He acquired 7,603 shares of common stock as restricted stock units and 8,871 performance stock units in each of two separate awards.
According to the terms, 25% of the restricted stock units vest on each of February 15, 2027, February 15, 2028, February 15, 2029, and February 15, 2030, as long as he continues as a service provider. One performance stock unit award will pay out from 0% to 250% of 8,871 shares based on the company’s three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026–2028, with vesting on December 31, 2028. The other performance stock unit award will pay out from 0% to 250% of 8,871 shares based on relative total shareholder return for the fiscal year ending December 31, 2028, subject to continued service.
Davies Scott M reported acquisition or exercise transactions in this Form 4 filing.
Illumina, Inc. Chief Legal Officer Scott M. Davies reported equity awards in the form of restricted stock units and performance stock units. He received 5,849 shares of common stock as restricted stock units that vest in four equal annual installments on February 15 of 2027, 2028, 2029, and 2030, subject to continued service.
He was also granted 6,824 performance stock units tied to three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026-2028, vesting on December 31, 2028, and 6,824 performance stock units tied to relative total shareholder return for the fiscal year ending December 31, 2028. For each performance award, the actual shares delivered can range from 0% to 250% of the target amount based on performance against predefined objectives and continued service.
ILLUMINA, INC. reported that SVP and Chief Financial Officer Ankur Dhingra acquired equity awards on March 5, 2026. He received 9,358 shares of common stock as restricted stock units, which vest 25% each on February 15 of 2027, 2028, 2029, and 2030, subject to continued service.
He was also granted 10,918 performance stock units tied to three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026–2028, and 10,918 performance stock units tied to relative total shareholder return for the fiscal year ending December 31, 2028. Each performance unit can settle into between 0% and 250% of the stated amount based on predefined objectives and continued service, and he held 34,264 shares of common stock directly after these grants.
Illumina, Inc. reported new equity awards for VP and Chief Accounting Officer Scott D. Ericksen. On March 5, 2026, he acquired grants of performance share units and restricted stock units, all recorded as awards rather than open-market purchases.
The filing shows two grants of 1,609 performance share units each, with the ultimate shares to be issued ranging from 0% to 250% of these amounts based on Illumina’s three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026–2028 and on relative total shareholder return for the fiscal year ending December 31, 2028.
He also received 3,217 shares of common stock in the form of restricted stock units. These RSUs vest in four equal installments of 25% on February 15, 2027, February 15, 2028, February 15, 2029, and February 15, 2030, conditioned on his continued service.
Leckman Patricia reported acquisition or exercise transactions in this Form 4 filing.
Illumina, Inc. executive Patricia Leckman received new equity awards in the form of restricted stock units and performance shares. On March 5, 2026, she was granted 6,317 shares of common stock as restricted stock units that vest in four equal 25% installments each February 15 from 2027 through 2030, subject to continued service.
She was also granted two separate awards of 7,369 performance stock units each. One is tied to Illumina’s three-year average consolidated non-GAAP earnings per share growth for fiscal years 2026–2028, vesting on December 31, 2028. The other is tied to the company’s relative total shareholder return for the fiscal year ending December 31, 2028. For each performance award, the actual shares ultimately issued can range from 0% to 250% of the stated amount, based on the company’s performance against predefined objectives and her continued service.
Illumina, Inc. reported that Chief of Global Operations Kevin Carl Pegels acquired new equity awards on March 5, 2026. He received 6,317 shares of common stock as restricted stock units at a reference price of $128.24 per share, vesting 25% each on February 15, 2027, February 15, 2028, February 15, 2029, and February 15, 2030, contingent on continued service.
He was also granted two tranches of performance stock units, each for 7,369 performance shares. One tranche vests on December 31, 2028 based on three-year average consolidated non-GAAP EPS growth for fiscal years 2026–2028, and the other on relative total shareholder return for the fiscal year ending December 31, 2028. In both cases, payout can range from 0% to 250% of the target amount, depending on performance and continued service. Following the common stock grant, he directly owned 29,038 shares of Illumina common stock.